Communiqués Evaxion Biotech A/S

Actions

EVAX

US29970R2040

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 07/06/2024			Varia. 5j.	Varia. 1 janv.
3,39 ^USD	-3,83 %		-7,63 %	-50,56 %

04/06	Les actions européennes négociées aux États-Unis et les American Depositary Receipts sont orientés à la baisse dans les échanges de mardi	MT
03/06	Les actions européennes échangées aux Etats-Unis et les American Depositary Receipts chutent dans les échanges de lundi	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX-01 Vaccine at the ASCO Annual Meeting 2024	03/06	AQ
Evaxion Announces Business Update and First Quarter 2024 Financial Results	28/05	AQ
Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024	23/05	AQ
Evaxion Receives Nasdaq Notification	10/05	AQ
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01	17/04	AQ
Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection	02/04	AQ
16 APRIL 2024 AT 15:00 (CEST) - Form 6-K	29/03	PU
Evaxion Announces Business Update and Full Year 2023 Financial Results	27/03	AQ
Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform	19/03	AQ
Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations	29/02	AQ
BioStock: Evaxion partners with MSD for vaccine development	28/02	AQ
Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD	20/02	AQ
Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement	07/02	AQ
Evaxion Announces Closing of $15 Million Public Offering	06/02	AQ
Evaxion Biotech Announces Pricing of $15 Million Public Offering	01/02	AQ
BioStock: Evaxion to develop novel precision cancer vaccine concept	31/01	AQ
Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets	24/01	AQ
Evaxion Announces Completion of ADS Ratio Change	22/01	GL
Evaxion Announces Completion of ADS Ratio Change	22/01	AQ
Evaxion annonce un plan visant à mettre en œuvre la modification du ratio de ses ADS	09/01	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Evaxion Biotech A/S

Actions

EVAX

US29970R2040

Communiqués

Filtres